SCHEMBL3353839

SCHEMBL3353839

CC(C)(C)OC(=O)C(N)(Br)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
KCNN4 O15554 2/20 0.46
CYP2C19 P33261 2/20 0.46
HIF1A Q16665 1/20 0.46
GRM6 O15303 1/20 0.41
ALDH1A1 P00352 2/20 0.41
ALOX15 P16050 1/20 0.41
BCHE P06276 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27876436 0.85 CYP1A2 (0.47) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL5982884 0.81 CYP1A2 (0.49) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL27872103 0.81 CYP1A2 (0.49) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL9545277 0.81 CYP1A2 (0.49) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL5767 0.81 CYP1A2 (0.44) CYP1A2CYP2D6MAPTKMT2AKCNN4
Hydrogen Peroxide SCHEMBL27880626 0.80 KCNN4 (0.64) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL491371 0.80 KCNN4 (0.64) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL28077402 0.80 KCNN4 (0.48) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL1624876 0.79 CYP2C19 (0.44) CYP1A2CYP2D6MAPTKMT2AKCNN4
SCHEMBL22164590 0.79 CYP1A2 (0.42) CYP1A2CYP2D6MAPTKMT2AKCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US disclosed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 CYP1A2 1897/4885CYP2D6 2162/4885MAPT 675/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CYP1A2 3371/4885CYP2D6 4009/4885MAPT 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.